FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家银行表示，SS&C Technologies第一季度业绩稳健，并强烈预期将进行股票回购。

-- 加拿大皇家银行资本市场（RBC Capital Markets）在周五发送的电子邮件报告中指出，SS&C Technologies (SSNC) 在宏观经济环境严峻的情况下，第一季度业绩表现稳健，有机增长率达5%，并预计第二季度增长率中值为5.6%。同时，管理层对股票回购计划充满信心。 报告还指出，由于代币化和人工智能仍是围绕该股的主要讨论焦点，SS&C Technologies 将于下周推出人工智能编排平台，并在支持客户进行资产代币化方面取得了进展。 报告指出，尽管同比增长依然稳健，但 GlobeOp 部门第一季度环比增速放缓 250 个基点，而 Global Investor and Distribution Solutions 部门下半年将面临更严峻的业绩基数。该券商表示，第一季度营收留存率为 96.7%，高于上一季度的 96.4% 和去年同期的 97.1%。 加拿大皇家银行（RBC）将SS&C Technologies 2026年的营收和调整后每股收益预期分别从67.1亿美元和6.83美元上调至67.6亿美元和6.92美元。同时，RBC还将2027年的营收和调整后每股收益预期从70.6亿美元和7.45美元上调至71.1亿美元和7.50美元。 RBC维持对SS&C Technologies的“跑赢大盘”评级，目标价为89美元。

Price: $66.56, Change: $-3.50, Percent Change: -5.00%

Related Articles

Asia

Update: Origin Energy Reports Lower March Quarter Production; Shares Fall 3%

(Updates to add stock movement in the headline and last paragraph)Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.The company's shares fell 3% in recent Monday trade.

$ASX:ORG
Asia

Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program

Alterity Therapeutics (ASX:ATH) said it received positive feedback from a second type C meeting with the US Food and Drug Administration (FDA) on its planned phase three program for drug candidate ATH434, aimed at treating multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.MSA is a progressive neurodegenerative disorder affecting autonomic and motor function with no approved disease-modifying therapies.The US FDA provided supportive written feedback on the program's chemistry, manufacturing, and controls, complementing earlier guidance from a separate type C meeting on clinical pharmacology and non-clinical development, the filing added.

$ASX:ATH
Asia

Xinyuan Property Management's CFO Resigns

Xinyuan Property Management Service's (HKG:1895) chief financial officer, Wang Yong, has resigned, effective April 26, according to a Monday Hong Kong bourse filing.Wang stepped down to devote more time to personal commitments, the company said.The company said the resignation will not affect its normal operations, with Wang's duties to be reallocated internally on an interim basis.Xinyuan Property Management added that it is seeking a suitable replacement for the chief financial officer role.

$HKG:1895